In this article, we discuss 5 cheap pharmaceutical stocks for 2022. If you want to read our detailed analysis of these stocks, go directly to 10 Cheap Pharmaceutical Stocks For 2022.
5. Evolus, Inc. (NASDAQ:EOLS)
Number of Hedge Fund Holders: 12
Real-Time Share Price as of February 15: $8.85
Evolus, Inc. (NASDAQ:EOLS) operates as a medical aesthetics firm. On January 20, Truist analyst Gregory Fraser upgraded the stock to Buy from Hold with a price target of $11, noting that the strong fundamentals of the firm indicated it was well-positioned for the launch of new drugs and the chance to evolve the business model to suit other products.
Elite hedge funds hold large stakes in Evolus, Inc. (NASDAQ:EOLS). At the end of the third quarter of 2021, 12 hedge funds in the database of Insider Monkey held stakes worth $28 million in Evolus, Inc. (NASDAQ:EOLS), the same as in the previous quarter worth $42 million.
4. Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)
Number of Hedge Fund Holders: 16
Real-Time Share Price as of February 15: $2.81
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) is a biopharma firm that develops therapies for cancer using protein design technology. One of the leading pipeline drugs for the firm is NL-201, a protein that seeks to act as a therapeutic for the treatment of renal cell carcinoma and melanoma, among other cancers.
Top hedge funds are exceedingly bullish on Neoleukin Therapeutics, Inc. (NASDAQ:NLTX). Among the hedge funds being tracked by Insider Monkey, California-based investment firm Redmile Group is a leading shareholder in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX), with 3.5 million shares worth more than $25 million.
3. Leap Therapeutics, Inc. (NASDAQ:LPTX)
Number of Hedge Fund Holders: 21
Real-Time Share Price as of February 15: $2.24
Leap Therapeutics, Inc. (NASDAQ:LPTX) is a biopharma firm developing therapies for cancer. There is positive hedge fund sentiment around the company. At the end of the third quarter of 2021, 21 hedge funds in the database of Insider Monkey held stakes worth $115 million in Leap Therapeutics, Inc. (NASDAQ:LPTX), up from 9 the preceding quarter worth $23 million.
On January 31, Leap Therapeutics, Inc. (NASDAQ:LPTX) announced that it had entered into an agreement with Leica Biosystems, a cancer diagnostics firm, to develop a diagnostic that will support clinical development of anticancer therapies through detection of Dickkopf-related protein 1.
2. Kaleido Biosciences, Inc. (NASDAQ:KLDO)
Number of Hedge Fund Holders: 4
Real-Time Share Price as of February 15: $1.57
Kaleido Biosciences, Inc. (NASDAQ:KLDO) is a clinical-stage healthcare firm. Major hedge funds hold large stakes in the company. Among the hedge funds being tracked by Insider Monkey, California-based investment firm Palo Alto Investors is a leading shareholder in Kaleido Biosciences, Inc. (NASDAQ:KLDO), with 786,400 shares worth more than $4.2 million.
Kaleido Biosciences, Inc. (NASDAQ:KLDO) is working on the development of drugs related to the treatment of urea cycle disorder, ulcerative colitis, hepatic encephalopathy, and the COVID-19 disease, among others.
1. Agile Therapeutics, Inc. (NASDAQ:AGRX)
Number of Hedge Fund Holders: 6
Real-Time Share Price as of February 15: $0.31
Agile Therapeutics, Inc. (NASDAQ:AGRX) operates as a healthcare firm focused on women. It is based in New Jersey. The company makes and sells prescription contraceptive products. One of the leading products of the firm is Twirla, a once-weekly prescription contraceptive patch. The firm has several Twirla-related pipeline projects as well.
Agile Therapeutics, Inc. (NASDAQ:AGRX) has attracted the interest of top investment firms on Wall Street. Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Perceptive Advisors is a leading shareholder in Agile Therapeutics, Inc. (NASDAQ:AGRX), with 15.9 million shares worth more than $15 million.
You can also take a peek at 10 Best Healthcare Dividend Stocks to Buy Now and 10 Dividend Stocks with Over 20 Years of Dividend Increases.
